| Trial ID: | L4945 |
| Source ID: | NCT00272090
|
| Associated Drug: |
Insulin Glargine
|
| Title: |
Insulin Glargine in Type 1 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 1
|
| Interventions: |
DRUG: Insulin glargine
|
| Outcome Measures: |
Primary: severe nocturnal hypoglycemias will be measured throughout the study period. | Secondary: HbA1c will be measured at basal and 8/16 weeks after start of treatment|8 point glucose profile will be measured during last 2 weeks before each scheduled visit|severe hypoglycemias and nocturnal hypoglycemias will be measured throughout the study period.
|
| Sponsor/Collaborators: |
Sponsor: Sanofi
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
489
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2002-11
|
| Completion Date: |
2005-12
|
| Results First Posted: |
|
| Last Update Posted: |
2011-06-08
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00272090
|
